Design Therapeutics, Inc. (DSGN) Current Ratio
- Current ratio · latest quarter: Value 18.86×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 18.86× | Current assets / current liabilities. $212.01M ÷ $11.24M ≈ 18.86× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 212.01M USD | Assets, Current |
| Current obligations | 11.24M USD | Liabilities, Current |
| Cash and equivalents | 12.91M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 194.49M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 3.14M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $212.01M | $11.24M | $12.91M | $194.49M | (m) | (m) | $3.14M | (m) | 18.86× |
| 2026-03-31 | $227.05M | $10.19M | $12.77M | $210.05M | (m) | (m) | $2.28M | (m) | 22.28× |
| 2025-12-31 | $223.78M | $13.05M | $16.86M | $202.99M | (m) | (m) | $2.31M | (m) | 17.14× |
| 2025-09-30 | $209.03M | $11.17M | $15.09M | $190.88M | (m) | (m) | $1.91M | (m) | 18.71× |
| 2025-06-30 | $219.79M | $8.75M | $19.70M | $196.57M | (m) | (m) | $1.01M | (m) | 25.13× |
| 2025-03-31 | $233.64M | $8.24M | $13.67M | $216.01M | (m) | (m) | $3.18M | (m) | 28.37× |
| 2024-12-31 | $248.04M | $8.46M | $22.56M | $222.91M | (m) | (m) | $2.19M | (m) | 29.31× |
| 2024-09-30 | $257.24M | $7.43M | $30.33M | $223.75M | (m) | (m) | $1.47M | (m) | 34.61× |
| 2024-06-30 | $264.84M | $6.39M | $45.70M | $215.32M | (m) | (m) | $1.30M | (m) | 41.42× |
| 2024-03-31 | $273.89M | $7.09M | $29.40M | $241.29M | (m) | (m) | $1.37M | (m) | 38.61× |
| 2023-12-31 | $284.58M | $9.62M | $21.20M | $260.60M | (m) | (m) | $1.94M | (m) | 29.58× |
| 2023-09-30 | $294.54M | $12.39M | $27.94M | $263.00M | (m) | (m) | $2.21M | (m) | 23.77× |
| 2023-06-30 | $306.05M | $12.13M | $27.20M | $275.89M | (m) | (m) | $1.92M | (m) | 25.22× |
| 2023-03-31 | $318.94M | $9.05M | $28.81M | $286.58M | (m) | (m) | $2.74M | (m) | 35.25× |
| 2022-12-31 | $335.12M | $10.78M | $26.50M | $303.89M | (m) | (m) | $3.02M | (m) | 31.10× |
| 2022-09-30 | $348.49M | $10.41M | $42.52M | $301.72M | (m) | (m) | $2.62M | (m) | 33.47× |
| 2022-06-30 | $361.72M | $7.39M | $119.65M | $239.72M | (m) | (m) | $2.07M | (m) | 48.96× |
| 2022-03-31 | $373.87M | $5.48M | $287.31M | $83.91M | (m) | (m) | $1.90M | (m) | 68.22× |
| 2021-12-31 | $385.44M | $5.28M | $298.57M | $85.50M | (m) | (m) | $1.62M | (m) | 72.96× |
| 2021-09-30 | $395.29M | $5.50M | $357.66M | $36.06M | (m) | (m) | $2.22M | (m) | 71.81× |
| 2021-06-30 | $404.88M | $3.40M | $370.84M | $32.00M | (m) | (m) | $1.58M | (m) | 118.91× |
| 2021-03-31 | $411.75M | $3.71M | $400.69M | $10.65M | (m) | (m) | $2.03M | (m) | 111.10× |
| 2020-12-31 | $36.23M | $2.33M | $2.38M | $33.71M | (m) | (m) | $1.40M | (m) | 15.55× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |